hsa-mir-331: Hsa-mir-331 is a microRNA that has been studied in various contexts. It has been used as an endogenous control in quantitative PCR experiments [PMC5386650]. Prediction analysis based on TargetScan revealed that hsa-mir-331 has binding sites for multiple miRNAs [PMC7497355]. Hsa-mir-331 has also been detected in follicular fluid samples [PMC6242846]. It is highly expressed in certain conditions, such as sRNAs associated with tumorigenesis and poor prognosis in hepatocellular carcinoma [PMC7797118] and liver cancer tsRNA [PMC8843861]. Hsa-mir-331 is also involved in regulating gene expression and cell migration, such as inhibiting glioblastoma cell migration and interfering with cisplatin resistance in hepatocellular carcinoma cells [PMC8843861] [PMC9816852]. Additionally, hsa-mir-331 has been found to be differentially expressed in various diseases, including psoriasis, neuroblastoma, and medulloblastoma [PMC3110257] [PMC5206712] [PMC9278893]. It is part of prognostic models for neuroblastoma and is associated with overall survival rates of patients with neuroblastoma [PMC9278893]. Hsa-mir-331 expression levels have also been linked to prognosis, with higher expression levels associated with a good prognosis for neuroblastoma patients.